Fosigotifator

DRUG5 trials

Sponsors

AbbVie, Calico Life Sciences LLC, McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions

ALSAmyotrophic Lateral SclerosisCree LeukoencephalopathyMajor Depressive Disorder (MDD)Vanishing White MatterVanishing White Matter Disease

Phase 1

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

TerminatedNCT04948645

AbbVieALS, Amyotrophic Lateral Sclerosis

Start: 2021-09-22End: 2025-07-15Updated: 2025-08-01

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

RecruitingNCT05757141

Calico Life Sciences LLCVanishing White Matter Disease

Start: 2023-03-13End: 2035-10-01Target: 50Updated: 2026-07-01

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

TerminatedNCT06618118

AbbVieMajor Depressive Disorder (MDD)

Start: 2024-10-23End: 2025-09-23Updated: 2025-09-30

Unknown Phase

Expanded Access to Fosigotifator

AbbVieCree Leukoencephalopathy, Vanishing White Matter

Updated: 2026-01-14

Single Patient Investigational Treatment for Cree Leukoencephalopathy

Active, not recruitingNCT07300397

McGill University Health Centre/Research Institute of the McGill University Health CentreCree Leukoencephalopathy

Start: 2025-12-03End: 2029-01-03Target: 1Updated: 2026-01-16